1. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

   • Nicky A. Beelen
   • Femke A. I. Ehlers
   • Lotte Wieten

   Review Open access 19 October 2022 Pages: 797 - 804

   

2. Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis

   • Kathryn Owen
   • Ramy Ghaly
   • Fiona Thistlethwaite

   Review Open access 31 October 2022 Pages: 805 - 814

   

3. Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities

   • Zhen Lu
   • Eun-Ah Bae
   • Serge Y. Fuchs

   Research 05 September 2022 Pages: 815 - 826

   

4. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

   • Marta Español-Rego
   • Carlos Fernández-Martos
   • Joan Maurel

   Research Open access 09 September 2022 Pages: 827 - 840

   

5. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

   • Wataru Fukuokaya
   • Takafumi Yanagisawa
   • Takahiro Kimura

   Research 14 September 2022 Pages: 841 - 849

   

6. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer

   • Nabeel Kajihara
   • Takuto Kobayashi
   • Ken-ichiro Seino

   Research 14 September 2022 Pages: 851 - 864

   

7. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy

   • Riki Okita
   • Yuka Mimura-Kimura
   • Kazunori Okabe

   Research 17 September 2022 Pages: 865 - 879

   

8. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma

   • Jianhua Liu
   • Hao Chen
   • Yi-Long Wu

   Research 19 September 2022 Pages: 881 - 893

   

9. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification

   • Motaz Ashkar
   • Shruti Chandra
   • Robert R. McWilliams

   Research 26 September 2022 Pages: 895 - 901

   

10. ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth

    • Jing Li
    • Chenguang Zhao
    • Jie Qin

    Research 26 September 2022 Pages: 903 - 916

    

11. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer

    • Ke Li
    • Jing Xu
    • Yu Kang

    Research Open access 27 September 2022 Pages: 917 - 928

    

12. Live attenuated VZV vaccination induces antitumor immunity in ATLL patients

    • Tatsuro Jo
    • Ritsuko Kubota-Koketsu
    • Kazuto Shigematsu

    Research Open access 01 October 2022 Pages: 929 - 944

    

13. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

    • Jeffrey S. Weber
    • Tayla Poretta
    • Alexander N. Shoushtari

    Research Open access 05 October 2022 Pages: 945 - 954

    

14. Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

    • Jeffrey S. Weber
    • Tayla Poretta
    • Alexander N. Shoushtari

    Correction Open access 20 December 2022 Pages: 955 - 955

15. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement

    • Masaya Suematsu
    • Shigeki Yagyu
    • Tomoko Iehara

    Research 10 October 2022 Pages: 957 - 968

    

16. αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade

    • Mingzhu Pan
    • Fei Wang
    • Juan Zhang

    Research 13 October 2022 Pages: 969 - 984

    

17. Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer

    • Ranran Shi
    • Xiuman Zhou
    • Yanfeng Gao

    Research 17 October 2022 Pages: 985 - 1001

    

18. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma

    • Lavinia Patricia Mocan
    • Rares Craciun
    • Carmen Mihaela Mihu

    Research 17 October 2022 Pages: 1003 - 1014

    

19. Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8⁺ T cell function

    • Yu Ping
    • Jiqi Shan
    • Yi Zhang

    Research 20 October 2022 Pages: 1015 - 1027

    

20. Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer

    • Wei Guo
    • Qilin Huai
    • Jie He

    Research Open access 29 October 2022 Pages: 1029 - 1045

    

21. Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE₂

    • Qingsheng Li
    • Kevin E. Goggin
    • Nejat K. Egilmez

    Brief Report 08 September 2022 Pages: 1047 - 1058

    

22. Correction to: Anti‑PD‑1 antibody‑activated Th17 cells subvert re‑invigoration of antitumor cytotoxic T‑lymphocytes via myeloid cell‑derived COX‑2/PGE₂

    • Qingsheng Li
    • Kevin E. Goggin
    • Nejat K. Egilmez

    Correction 18 February 2023 Pages: 1059 - 1059